Collegium Pharmaceutical (NASDAQ:COLL) Receives "Hold (C)" Rating from Weiss Ratings

Key Points

• Collegium Pharmaceutical received a "hold (C)" rating from Weiss Ratings, despite other analysts upgrading its stock to "strong-buy" with a price target of $44.00.
• Shares of COLL have recently traded down 0.8%, with a current price of $33.13, compared to a 52-week range of $23.23 to $39.95.
• The company has initiated a $150 million share buyback plan, indicating that its board believes the stock may be undervalued.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report)'s stock had its "hold (c)" rating reaffirmed by Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other equities analysts have also recently issued reports about the company. HC Wainwright upgraded Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 price target for the company in a report on Monday, August 11th. Wall Street Zen upgraded Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, Zacks Research upgraded Collegium Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of "Buy" and an average price target of $42.33.

Collegium Pharmaceutical Trading Down 0.8%

Shares of COLL traded down $0.26 during midday trading on Wednesday, reaching $33.13. The company had a trading volume of 275,911 shares, compared to its average volume of 382,503. Collegium Pharmaceutical has a 1-year low of $23.23 and a 1-year high of $39.95. The stock has a market cap of $1.04 billion, a PE ratio of 31.86 and a beta of 0.65. The firm has a 50 day simple moving average of $36.08 and a 200-day simple moving average of $31.61. The company has a quick ratio of 1.10, a current ratio of 1.18 and a debt-to-equity ratio of 3.27.

Collegium Pharmaceutical announced that its board has authorized a share buyback plan on Monday, July 7th that allows the company to repurchase $150.00 million in outstanding shares. This repurchase authorization allows the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board of directors believes its shares are undervalued.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Gino Santini sold 5,405 shares of the business's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $37.19, for a total transaction of $201,011.95. Following the sale, the director directly owned 95,042 shares in the company, valued at approximately $3,534,611.98. The trade was a 5.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Scott Dreyer sold 16,389 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $38.21, for a total value of $626,223.69. Following the sale, the executive vice president owned 103,613 shares in the company, valued at approximately $3,959,052.73. The trade was a 13.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,792 shares of company stock valued at $2,084,207 in the last three months. 2.51% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. lifted its position in Collegium Pharmaceutical by 1.4% during the second quarter. Franklin Resources Inc. now owns 29,172 shares of the specialty pharmaceutical company's stock worth $863,000 after buying an additional 409 shares during the period. SummerHaven Investment Management LLC grew its stake in shares of Collegium Pharmaceutical by 1.9% in the first quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company's stock valued at $727,000 after buying an additional 448 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Collegium Pharmaceutical by 4.5% in the first quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company's stock valued at $326,000 after buying an additional 477 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Collegium Pharmaceutical by 0.6% in the second quarter. Legal & General Group Plc now owns 89,829 shares of the specialty pharmaceutical company's stock valued at $2,656,000 after buying an additional 531 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in Collegium Pharmaceutical by 6.9% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,252 shares of the specialty pharmaceutical company's stock valued at $244,000 after purchasing an additional 534 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.